Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

NO_LONGER_AVAILABLE

Conditions studied: Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), Acute Myeloid Leukemia (6 Patients)

In brief

GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.

Key facts

Study ID

NCT03420430

Run by

Genelux Corporation

Last updated by the study team

2024-09-25

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of advanced cancers with no standard of care option for treatment.
• Willing and able to provide written, signed informed consent.
• Use of adequate contraception.
• Negative pregnancy test.

You may not qualify if…

• Have not recovered from severe adverse events from prior therapy.
• Major surgery occurred within 28 days prior to treatment.
• Known immune system disorders such as HIV, or active hepatitis B or C infection.
• Clinically significant cardiac disease (New York Heart Association Class III or IV).
• Have received prior therapy with an oncolytic virus of any type.
• Be receiving antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, ST-246).
• Have known allergy to ovalbumin or other egg products.
• Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed skin wounds or ulcers) as assessed by the treating physician.

Where it is running

• Florida Hospital Cancer Institute — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.